EP Patent

EP2345657A1 — Modified fluorinated nucleoside analogues

Assigned to Gilead Pharmasset LLC · Expires 2011-07-20 · 15y expired

What this patent protects

The disclosed invention provides compositions and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially humans, using a (2'R)-2'-deoxy-2'-fluoro-2'-…

USPTO Abstract

The disclosed invention provides compositions and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially humans, using a (2'R)-2'-deoxy-2'-fluoro-2'- C -methyl nucleosides, or a pharmaceutically acceptable salt or prodrug thereof.

Drugs covered by this patent

Patent Metadata

Patent number: EP2345657A1
Jurisdiction: EP
Classification: —
Expires: 2011-07-20
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Pharmasset LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.